Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $10 Million
Tiziana Life Sciences announced a registered direct offering of 5,263,158 common shares at $0.95 per share, raising approximately $5 million in gross proceeds. The company also issued an option for investors to acquire an additional 5,263,158 shares at the same price within 75 days, potentially raising another $5 million. The proceeds will fund Phase 2a clinical trials for intranasal foralumab in multiple sclerosis patients, accelerate Alzheimer's disease research, develop foralumab for other indications, and support working capital needs. The offering is expected to close around November 1, 2024.